Literature DB >> 33032867

Cholangiocarcinoma miscoding in hepatobiliary centres.

Shaun Selvadurai1, Kulbir Mann2, Sanjena Mithra3, John Bridgewater4, Hassan Malik2, Shahid A Khan5.   

Abstract

INTRODUCTION: Cholangiocarcinoma (CCA) are sub-divided into intrahepatic (iCCA) or extrahepatic (eCCA). eCCA are further subdivided into perihilar (pCCA) and distal (dCCA). Current and previous versions of the WHO International Coding of Disease and Oncology classifications (ICD) have separate topography codes for iCCA and eCCA, but none for pCCA. Over recent decades, multiple studies report rising incidence rates of iCCA with declining rates of eCCA, without reference to pCCA. We hypothesised the lack of a specific code for pCCA has led to errors CCA coding, specifically with miscoding of pCCA as iCCA.
METHODS: Clinical notes of cases coded as hepatobiliary carcinoma using ICD-10 criteria (C22.1/Intrahepatic Bile Duct carcinoma, C24.0/Extrahepatic Bile Duct carcinoma, C23X/Malignant Neoplasm Gall Bladder, C22.0/Malignant Neoplasm Liver Cell Carcinoma) over a 2 year period (2015-2017), were reviewed by two independent clinicians at three independent UK regional HepatoPancreatoBiliary centres. The agreed final diagnosis was compared to the originally allocated ICD-10 code.
RESULTS: Of the 625 CCA cases fully reviewed, 226 were coded as C22.1/iCCA. 98 (43%) of these were true iCCA and coded correctly, while 76 cases (34%) were actually pCCA. 92% all pCCA cases were incorrectly coded as iCCA.
CONCLUSION: CCA coding misclassification in UK HPB centres is common, particularly the miscoding of pCCA, which is extrahepatic and the commonest form of CCA, as iCCA. This may be contributing to apparent rising incidence rates of iCCA. Our findings confirm the need to implement distinct topographical codes for iCCA, pCCA and dCCA in future iterations of ICD.
Copyright © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Year:  2020        PMID: 33032867     DOI: 10.1016/j.ejso.2020.09.039

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  6 in total

1.  The 11th revision of the International Statistical Classification of Disease and Related Health Problems and Cholangiocarcinoma.

Authors:  Shijie Cai; Shivan Sivakumar
Journal:  Hepatobiliary Surg Nutr       Date:  2022-04       Impact factor: 7.293

Review 2.  Cholangiocarcinoma.

Authors:  Paul J Brindley; Melinda Bachini; Sumera I Ilyas; Shahid A Khan; Alex Loukas; Alphonse E Sirica; Bin Tean Teh; Sopit Wongkham; Gregory J Gores
Journal:  Nat Rev Dis Primers       Date:  2021-09-09       Impact factor: 65.038

3.  Menopausal hormone therapy and risk of biliary tract cancers.

Authors:  Sarah S Jackson; Ruth M Pfeiffer; Chiara Gabbi; Lesley Anderson; Shahinaz M Gadalla; Jill Koshiol
Journal:  Hepatology       Date:  2022-02       Impact factor: 17.298

Review 4.  Current challenges to underpinning the genetic basis for cholangiocarcinoma.

Authors:  Antonio Cigliano; Xin Chen; Diego F Calvisi
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2021-04-23       Impact factor: 3.869

5.  A look back at cholangiocarcinoma in Finland.

Authors:  Laura Izquierdo-Sanchez; Jesus M Banales; Pedro M Rodrigues
Journal:  United European Gastroenterol J       Date:  2021-09-28       Impact factor: 4.623

6.  Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017.

Authors:  Milind Javle; Sunyoung Lee; Nilofer S Azad; Mitesh J Borad; Robin Kate Kelley; Smitha Sivaraman; Anna Teschemaker; Ishveen Chopra; Nora Janjan; Shreekant Parasuraman; Tanios S Bekaii-Saab
Journal:  Oncologist       Date:  2022-10-01       Impact factor: 5.837

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.